Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Dynamic mutational evolution and transcriptomic remodeling on 3rd-generation TKI therapy in TKI-resistant patients with chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoshuai ZhangZLZongru LiYQYa-Zhen Qin

Discussion

Loading...

Member takes

Overview

Observational analysis reveals distinct treatment outcomes in CML linked to resistance mechanisms and gene expression profiles.

Key Points

  • Treated CML patients saw different responses, with clonal evolution correlating with therapy outcomes.
  • Immune activation and leukemic stem cell suppression were observed in responders during therapy.
  • Analysis involved targeted DNA and RNA sequencing in a diverse cohort of chronic myeloid leukemia patients.
  • Transcriptional changes during treatment can serve as early indicators of therapeutic failure, guiding personalized care.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5a3https://doi.org/10.1182/blood-2025-5540
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic evolution in CML patients from diagnosis to TKI failure: An analysis of 121 paired diagnosis and treatment failure samples2025
  2. 2Systematic molecular profiling to identify determinants of response to ibrutinib2025
  3. 3Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025
  4. 4Single-cell chromatin profiling reveals early epigenetic reprogramming, subtype-specific regulatory networks, and JAK/STAT–IRF vulnerabilities in high-risk chronic myeloid leukemia2025
  5. 5COMPARATIVE EFFICACY AND SAFETY OF NEW-GENERATION TYROSINE KINASE INHIBITORS IN ACHIEVING DEEP MOLECULAR REMISSION AND REMISSION WITHOUT TREATMENT IN CHRONIC MYELOID LEUKEMIA2025